



Glenmark Generics Limited

Press Release

For Immediate Release

Glenmark Launches Azathioprine Tablets in the U.S. Market

- Azathioprine is indicated as an adjunct for the prevention of rejection in kidney transplantation

November 20, 2008: Glenmark Generics Ltd's, US subsidiary has gained full marketing rights through an exclusive partnership to begin distributing Azathioprine 50mg Tablets in the United States.

Azathioprine is the generic equivalent of Imuran® tablets and is indicated as an adjunct for the prevention of rejection in renal homotransplantations (Kidney Transplantation). It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Total sales for the 12 month period ending June 2008 were approximately \$36 million as stated by IMS Health.

This product launch signifies Glenmark's commitment to enhance and augment its current portfolio of internal filings through the addition of external partnerships. Today, Glenmark is authorized to distribute 130 SKUs in the U.S. marketplace. The Company currently has 40 ANDAs in various stages of the approval process with U.S. FDA.

About Glenmark Generics Ltd.:

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America. The Company has a state-of-the-art manufacturing plant at Goa, India that is approved by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 30 USDMFs filed and/or approved along with several Canadian DMFs, EDMFs and CEPs/CoSs. [www.glenmark-generics.com]



Glenmark Generics Limited

About Glenmark Pharmaceuticals Ltd.:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Its shares are listed on India's two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). It employs over 5500 people across its global operations over 85 countries. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.], and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211 has been out-licensed to Eli Lilly & company. For more information on GPL, log on to <http://www.glenmarkpharma.com/>

For further information, please contact:

Jason D'Souza | Medha Satam

Glenmark, Mumbai, India

Tel: [+91 22] 40189919 / 40189993 Email : connect@glenmark-generics.com